![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Citalopram hydrobromide, Process II, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2021-462 - Rev 00
This Chemical Type CEP, issued on April 07, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2288 associated with this CEP further emphasizes